HealWELL AI Inc. Stock Price, News & Analysis

HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) has announced a strategic investment of USD$250,000 in Abstractive Health, a healthcare AI company specializing in automated patient summaries using proprietary generative AI technology. The investment is part of a broader funding round led by Rho Capital Partners. Concurrent with the investment, HEALWELL has entered into a commercial agreement with Abstractive Health, securing exclusive distribution rights for the Canadian outpatient healthcare market.

Abstractive Health's AI software leverages LLMs and generative AI to automate medical record summaries, streamlining healthcare documentation processes. HEALWELL plans to integrate Abstractive Health's technology into WELL Health Technologies' apps.health marketplace, expanding its suite of AI-enabled co-pilot technologies for healthcare providers.

HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), a healthcare technology company focused on AI and data science for preventative care, announces its participation in the 17th Annual LD Micro Main Event from October 28-30th, 2024, at the Luxe Sunset Boulevard Hotel in Los Angeles. Dr. Alexander Dobranowski, CEO of HEALWELL, will deliver a live presentation on Wednesday, October 30, 2024, at 10:30am PT and conduct in-person meetings.

Dr. Dobranowski expressed enthusiasm about sharing HEALWELL's story and showcasing their AI-driven clinical decision support systems. The event provides an opportunity to update existing shareholders and introduce the company to potential new U.S. investors. Chris Lahiji, Founder of LD Micro, emphasized the event's significance in the small and micro-cap industry.

HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, will participate in the 2024 Cantech Letter Investment Conference on October 9, 2024, in Toronto, Ontario. Dr. Alexander Dobranowski, CEO of HEALWELL, will deliver an investor presentation at 10:00 AM PT and participate in a keynote panel discussion titled 'Artificial Irrelevance? How Canadian Techs are Building Intelligence and Purpose into AI Solutions' at 8:30 AM. The panel will be moderated by Brady Fletcher, President of Roth Canada.

Both Dr. Dobranowski and Anthony Lam, CFO of HEALWELL, will attend the conference and conduct in-person 1x1 meetings with investors. The event provides an opportunity for HEALWELL to showcase its vision of revolutionizing healthcare through AI-driven preventative care and engage with the investment community.

HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) has announced that its subsidiary, BioPharma Services Inc., is expanding into late-stage patient trials by integrating Canadian Phase Onward (CPO). This strategic move transforms BioPharma into a full-service Contract Research Organization (CRO), capable of managing clinical trials across all phases of drug development. The integration also involves incorporating HEALWELL's AI and data science capabilities to enhance research, disease detection, and patient identification.

Key benefits include:

• Expanded capabilities across all clinical trial stages
• Increased patient access through WELL Health's populations
• Enhanced research infrastructure with a robust referral network
• Integration of AI for improved patient identification and trial efficiency

BioPharma has completed over 2,200 clinical trials with approximately 250 pharma clients globally, including 4 of the top 25 largest pharmaceutical companies.

HEALWELL AI Inc.'s subsidiary, Pentavere, has been nominated for a 2024 Prix Galien award in the Best Digital Health Startup category. This marks Pentavere's third nomination in three years. The Prix Galien is considered the most prestigious honor in the life sciences and pharmaceutical industry. To date, over 1 million patients have benefited from Pentavere's DARWEN™ AI system.

Pentavere will be presenting at several upcoming medical conferences, showcasing the capabilities of its DARWEN™ AI platform in generating real-world evidence and identifying patient cohorts with unmet needs. These conferences include the 46th ESPEN Congress, 66th ASTRO Annual Meeting, United European Gastroenterology Week, and the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting.

WELL Health's OceanMD and HEALWELL's Intrahealth have announced a strategic partnership to integrate OceanMD's leading eReferral system across Intrahealth's global network. This collaboration aims to enhance digital interoperability, streamline healthcare processes, and improve patient access to care. OceanMD's platform currently handles over 120,000 eReferrals and eConsults monthly and has secured contracts with Ontario, British Columbia, and Nova Scotia for provincial deployments.

The integration will allow healthcare providers to send, receive, and manage eReferrals directly from their EMR, simplifying workflows and improving patient care. This partnership is expected to reduce administrative burdens, enhance provider efficiency, and offer patients better access to their health data.

WELL Health's OceanMD and HEALWELL's Intrahealth have announced a strategic partnership to integrate OceanMD's eReferral system across Intrahealth's global network. This collaboration aims to enhance digital interoperability, streamline healthcare processes, and improve patient access to care. OceanMD's platform currently handles over 120,000 eReferrals and eConsults monthly and has secured contracts with Ontario, British Columbia, and Nova Scotia for provincial deployments.

The integration will allow healthcare providers to send, receive, and manage eReferrals directly from their EMR, simplifying workflows and improving patient care. This partnership is expected to reduce administrative burdens, enhance provider efficiency, and offer patients better access to their health data.

HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) reported record quarterly revenue of $5.44 million in Q2-2024, a 205% increase from Q2-2023. The company also achieved net income of $2.54 million, compared to a loss of $9.81 million in Q2-2023. This turnaround was primarily due to settling past liabilities and successful equity financing of $20 million.

Key highlights include:

• Adjusted Gross Profit of $3.76 million, up 669% year-over-year
• Adjusted Gross Margin of 69%, up from 27% in Q2-2023
• Cash balance of $19.82 million as of June 30, 2024
• Acquisition of BioPharma Services Inc. and Verosource Solutions Inc. on July 1, 2024

HEALWELL aims to reach a revenue run-rate approaching $100 million by year-end, driven by M&A activities and increased adoption of its AI-powered healthcare solutions.

HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, has announced it will release its Fiscal Second Quarter 2024 financial results for the period ended June 30, 2024, on Monday, August 12, 2024. The company will hold a conference call and simultaneous webcast to discuss its results on the same day at 5:30 pm EST (2:30 pm PST).

The call will be hosted by Dr. Alexander Dobranowski, Chief Executive Officer, and Anthony Lam, Chief Financial Officer. Attendees can join via webcast or phone, with pre-registration required for phone participation. The company has provided links for both webcast access and phone registration.